亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Adjuvant chemotherapy guided by circulating tumor DNA analysis in stage II colon cancer: The randomized DYNAMIC trial.

医学 奥沙利铂 临床终点 内科学 肿瘤科 结直肠癌 佐剂 随机对照试验 阶段(地层学) 置信区间 癌症 循环肿瘤DNA 临床试验 辅助化疗 古生物学 乳腺癌 生物
作者
Jeanne Tie,Joshua Cohen,Kamel Lahouel,Serigne Lo,Yuxuan Wang,Rachel O.L. Wong,Jeremy Shapiro,Samuel Harris,Muhammad Muzaffar Ali Khan Khattak,Matthew Burge,Marion O. Harris,James Lynam,Louise M. Nott,Fiona Day,Theresa M. Hayes,Nickolas Papadopoulos,Cristian Tomasetti,Kenneth W. Kinzler,Bert Vogelstein,Peter Gibbs
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:40 (17_suppl): LBA100-LBA100 被引量:5
标识
DOI:10.1200/jco.2022.40.17_suppl.lba100
摘要

LBA100 Background: The role of adjuvant chemotherapy (CT) in stage II colon cancer continues to be debated. The presence of circulating tumor DNA (ctDNA) after surgery predicts very poor recurrence-free survival (RFS), while its absence predicts a low recurrence risk. For ctDNA-positive cases the benefit of adjuvant CT is unknown. DYNAMIC was designed to assess if a ctDNA-guided approach could reduce the use of adjuvant CT without compromising recurrence risk. Methods: DYNAMIC is a multi-center randomized controlled phase II trial. Eligible patients had resected stage II colon cancer and were suitable for adjuvant CT. Patients were randomly assigned 2:1 to ctDNA-guided management or standard management (clinician-guided based on conventional criteria), after stratification for T stage and participating center location. Criteria for clinical low versus high risk were predefined. The Safe-SeqS tumor-informed personalized ctDNA assay was used. For ctDNA-guided management, a ctDNA-positive result at 4 or 7 weeks after surgery prompted oxaliplatin-based or fluoropyrimidine CT; ctDNA-negative patients were not treated. The primary efficacy endpoint was non-inferiority in RFS rate at 2 years. A key secondary endpoint was adjuvant CT use. The target sample size of 450 provided 80% power with 95% confidence to confirm non-inferiority between the two arms with a margin of 8.5%. Results: Of 455 patients randomized between Aug 2015 and Aug 2019, 302 were assigned to ctDNA-guided and 153 to standard management. Median follow-up was 37 months. In the ctDNA-guided arm, ctDNA analysis was successful in all but three patients; only two patients did not receive ctDNA-guided management. In the intention to treat population, fewer patients overall in the ctDNA-guided arm received adjuvant CT compared to standard management (15.3% vs 27.9%, odds ratio 2.14; P = 0.002), with the largest difference seen in patients with T4 or poorly differentiated tumors (odds ratios 6.22 and 6.31, respectively). Of those who received treatment, oxaliplatin-based doublet was more frequently administered than fluoropyrimidine alone for ctDNA-guided compared to standard management patients (62.2% vs. 9.8%; P < 0.001). ctDNA-guided management was non-inferior to standard management for 2-year RFS (93.5% vs 92.4%, difference 1.1%, 95% confidence interval, -4.1% to 6.2%). Following adjuvant CT, 3-year RFS for ctDNA-positive patients was 86.4%. Without adjuvant CT, 3-year RFS for ctDNA-negative patients was 92.5%, with a 3-year RFS of 96.7% in the clinical low risk subgroup. Conclusions: A ctDNA-guided approach to stage II colon cancer reduced adjuvant chemotherapy use without compromising recurrence-free survival. The low recurrence rate in ctDNA-positive patients who received chemotherapy suggests a survival benefit from adjuvant therapy. ctDNA-negative patients are unlikely to benefit from chemotherapy. Clinical trial information: ACTRN12615000381583.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
殷勤的半凡完成签到,获得积分10
17秒前
耍酷的手套完成签到,获得积分10
21秒前
27秒前
32秒前
充电宝的应助被爱学习的doge采纳,获得10
32秒前
32秒前
32秒前
32秒前
orixero的应助被爱学习的doge采纳,获得10
32秒前
隐形曼青的应助被爱学习的doge采纳,获得10
32秒前
在水一方的应助被爱学习的doge采纳,获得10
32秒前
大模型的应助被爱学习的doge采纳,获得10
32秒前
华仔的应助被爱学习的doge采纳,获得10
32秒前
香蕉觅云的应助被爱学习的doge采纳,获得10
39秒前
CodeCraft的应助被爱学习的doge采纳,获得10
39秒前
SciGPT的应助被爱学习的doge采纳,获得10
39秒前
隐形曼青的应助被爱学习的doge采纳,获得10
39秒前
小二郎的应助被爱学习的doge采纳,获得10
39秒前
852的应助被爱学习的doge采纳,获得10
39秒前
39秒前
田様的应助被爱学习的doge采纳,获得10
39秒前
脑洞疼的应助被爱学习的doge采纳,获得10
40秒前
bkagyin的应助被爱学习的doge采纳,获得10
40秒前
顺利水桃完成签到,获得积分10
41秒前
44秒前
乐乐的应助被mengdewen采纳,获得10
50秒前
53秒前
54秒前
55秒前
55秒前
55秒前
55秒前
55秒前
55秒前
56秒前
56秒前
56秒前
56秒前
56秒前
56秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179924
求助须知:如何正确求助?哪些是违规求助? 9570159
关于积分的说明 21808379
捐赠科研通 7775767
什么是DOI,文献DOI怎么找? 3433193
关于科研通互助平台的介绍 2557347
邀请新用户注册赠送积分活动 2478918